“…Consistent with the loss-of-function studies described above, pharmacological and genetic augmentation of eCB signaling via inhibition or deletion of 2-AG and AEA degradation decreases anxiety-like behaviors in a variety of preclinical models. For example, pharmacological inhibition of FAAH decreases unconditioned anxiety-like behaviors behavior in rats and mice in an array of behavioral tests including the light-dark box, the elevated-plus maze, the open-field test, and the novelty-induced suppression of feeding task (Duan et al, 2016;Hill et al, 2007;Kathuria et al, 2003;Kinsey et al, 2011;Moise et al, 2008;Morena et al, 2016a;Naidu et al, 2007;Patel and Hillard, 2006;Scherma et al, 2008). Moreover, genetic deletion of FAAH decreases anxiety-like behaviors via a CB1-dependent mechanism (Kathuria et al, 2003;Moreira et al, 2008).…”